<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Congenital long QT syndrome: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Congenital long QT syndrome: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Congenital long QT syndrome: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Schwartz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Ackerman, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K Triedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Asirvatham, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long QT syndrome (LQTS) is a disorder of ventricular myocardial repolarization characterized by a prolonged QT interval on the electrocardiogram (ECG)  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ) that can lead to symptomatic ventricular arrhythmias and an increased risk of sudden cardiac death (SCD) [
         <a href="#rid1">
          1
         </a>
         ]. The primary symptoms in patients with LQTS include syncope, seizures, sudden cardiac arrest (SCA), and SCD. This syndrome is associated with an increased risk of a characteristic life-threatening cardiac arrhythmia known as torsades de pointes or "twisting of the points"  (
         <a class="graphic graphic_waveform graphicRef73827" href="/z/d/graphic/73827.html" rel="external">
          waveform 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         LQTS may be congenital or acquired [
         <a href="#rid1">
          1,3-7
         </a>
         ]. Pathogenic variants in at least 17 genes have been identified thus far in patients with congenital LQTS. An estimated 75 to 80 percent of all congenital LQTS is accounted for by LQTS-causative variants in either
         <em>
          KCNQ1-
         </em>
         encoded Kv7.1 (LQT1),
         <em>
          KCNH2-
         </em>
         encoded Kv11.1 (LQT2), or
         <em>
          SCN5A
         </em>
         -encoded Nav1.5 (LQT3). The minor LQTS genotypes account for at most 5 percent of LQTS and are best referred to by their genetic cause rather than their numerical subtype (eg, CACNA1C-LQTS rather than LQT8)  (
         <a class="graphic graphic_table graphicRef114927" href="/z/d/graphic/114927.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Acquired LQTS usually results from undesired QT prolongation and potential for QT-triggered arrhythmias by either QT-prolonging disease states, QT-prolonging medications (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=988" target="_blank">
          www.crediblemeds.org
         </a>
         ), or QT-prolonging electrolyte disturbances  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The treatment of congenital LQTS will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and genetics of congenital LQTS, as well as issues related to the management of acquired LQTS, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1009.html" rel="external">
          "Congenital long QT syndrome: Pathophysiology and genetics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of genotype, age, and previous symptomatic/asymptomatic status, all patients with congenital LQTS should be advised of simple QT preventive measures and implement them whenever possible. These include avoidance of medications with QT-prolonging potential (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=988" target="_blank">
          www.crediblemeds.org
         </a>
         ); replacing electrolytes during vomiting and diarrheal illnesses, as both hypokalemia and hypomagnesemia can be QT aggravating; and lowering fever.
        </p>
        <p>
         Like the 2015 Heart Rhythm Society (HRS) guidelines, the 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines continue to recommend universal beta-blocker therapy for all patients with congenital LQTS, whether asymptomatic or symptomatic, in the absence of a contraindication [
         <a href="#rid8">
          8
         </a>
         ]. In the setting of breakthrough cardiac events while on beta-blocker therapy or in the setting of beta-blocker intolerance, patient-specific tailoring of therapy is appropriate, based on the assessed risk from the disease and the potential comorbidities of the various treatments under consideration with the patients and their families also involved in the shared decision making. Recommended options for treatment intensification may include one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other medications (such as
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left cardiac sympathetic denervation (LCSD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placement of a pacemaker to enable intentional atrial pacing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placement of an implantable cardioverter-defibrillator (ICD)
        </p>
        <p>
        </p>
        <p>
         The treatment of patients with congenital and acquired LQTS differs greatly because of pathophysiologic differences between the two forms. As an example, bradycardia is usually associated with torsades de pointes (TdP) in acquired LQTS, whereas catecholamine surges trigger TdP in congenital LQTS.
        </p>
        <p>
         The following discussion is limited to the treatment of congenital LQTS. The management of acquired LQTS is presented separately; it involves acute therapy of arrhythmia, discontinuation of any precipitating drug, and correction of any metabolic abnormalities such as hypokalemia or hypomagnesemia. The acute management of TdP is also discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias", section on 'Polymorphic ventricular tachycardia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Our approach to symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the appreciable risk of symptoms and SCD without treatment, all previously
         <strong>
          symptomatic
         </strong>
         patients with congenital LQTS should be treated [
         <a href="#rid9">
          9,10
         </a>
         ]. Our general approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with congenital LQTS should adhere to standard general preventive measures, such as the avoidance of medications known to prolong the QT interval (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=988" target="_blank">
          www.crediblemeds.org
         </a>
         ) and the aggressive treatment of electrolyte imbalances (eg, hypokalemia in the setting of vomiting, diarrhea, or diuretic use). (See
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management", section on 'Initial management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Athletes with LQTS who desire to remain athletes should be evaluated by an LQTS specialist to enable shared decision making to occur successfully. Importantly, there are laws in some countries that supersede professional society guidelines regarding return-to-play issues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients with congenital LQTS and a history of syncope or seizures, we recommend treatment with a beta blocker. We prefer
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         , given their superior efficacy in this patient population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with congenital LQTS who present with resuscitated SCA should be treated with a beta blocker, preferably
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         , given their superior efficacy in this patient population. Additionally, for most patients with congenital LQTS who present with resuscitated SCA while previously undiagnosed and therefore untreated, the treatment program should also include an ICD as secondary prevention. Potential exceptions to this include patients with previously undiagnosed and therefore untreated LQT1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with recurrent arrhythmic events in spite of maximally tolerated doses of a beta blocker, or for patients who discontinue beta blockers due to intolerable side effects, treatment intensification with either concomitant drug therapy, LCSD, and/or an ICD is recommended depending on the nature of the arrhythmic event, the genotype, and the patient's degree of QT prolongation at rest (ie, their resting QTc). The risks and benefits of each treatment intensification option need to be reviewed with the patient and shared decision making should be utilized to decide upon and implement the chosen therapeutic strategy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1133440097">
         <span class="h2">
          Physical activity and LQTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before tailoring any LQTS-specific therapies or recommending activity modification, it is vital to confirm the diagnosis of LQTS. Athletes are often flagged for the possibility of LQTS based on their pre-sports participation ECG screen. While a subsequent evaluation is necessary and appropriate, studies show that exercise can elicit a maladaptive remodeling in the repolarization reserve, yielding an acquired, reversible form of QT prolongation rather than congenital LQTS itself [
         <a href="#rid11">
          11
         </a>
         ]. If such an athlete's genetic test is negative and if their QT normalizes after detraining, they should not be classified as having LQTS or restricted from activity [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         After establishing the correct diagnosis of LQTS and implementing the initial treatment program, patients with LQTS can continue to be recreationally active, especially those with LQT2 and LQT3. In general, children and adolescents can resume participation in physical education classes and adults should be encouraged to stay aerobically active in accordance with national/international recommendations on active living.
        </p>
        <p>
         Athletes with LQTS who desire to remain competitive athletes should be evaluated by an LQTS specialist to enable shared decision making to occur successfully. Importantly, there are laws in some countries that supersede professional society guidelines regarding return-to-play issues.
        </p>
        <p>
         There is a divergence of opinions on competitive athletics for individuals with congenital LQTS [
         <a href="#rid12">
          12-15
         </a>
         ]. The 2015 AHA/ACC Scientific Statement on Eligibility and Disqualification Recommendations for Competitive Athletes discusses participation in competitive events and training sessions as allowable and dependent on the existence of an emergency action plan with an automated external defibrillator (AED) immediately available on site. However, a different approach is dictated by the previous European guidelines, which advise precautionary restriction from competitive sports in these instances.
        </p>
        <p>
         The differences in the American and European approaches are outlined as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following approach is proposed in the 2015 AHA/ACC Scientific Statement [
         <a href="#rid12">
          12,13
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asymptomatic persons who are genotype positive/phenotype negative (ie, with normal QTc at rest) can reasonably participate in all competitive sports with appropriate safety precautions, including avoidance of drugs known to exacerbate LQTS; avoidance and/or treatment of fever, hyperthermia, or heat exhaustion/heat stroke; electrolyte repletion; avoidance of dehydration; and establishment of an emergency action plan with an AED immediately available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptomatic (or previously symptomatic) patients, or patients with LQTS (QTc &gt;470 milliseconds in males or &gt;480 milliseconds in females), may consider participation in competitive athletics (with the exception of swimming in patients with LQT1 genotype) if they remain asymptomatic after three months of treatment and with appropriate cautionary measures, including an emergency action plan with an AED immediately available.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with LQTS and an ICD who have had three or more months without ICD therapy, participation in class IA sports  (
         <a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">
          figure 1
         </a>
         ) may be reasonable. Experts disagree on participation in higher levels of sport for patients with an ICD in place. Some experts feel that participation in sports with higher levels of exertion might be considered following counselling of the patient of the potential risks and appropriate cautionary measures, including an emergency action plan to implement should arrhythmias arise. However, other experts disagree and feel it is unwise to expose patients to the risk of ventricular arrhythmias and multiple shocks just to perform a competitive sport.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A different approach was stated in the previous European guidelines, which advise precautionary restriction from essentially all competitive sports, based in part on the considerations that the safety measures recommended by the 2015 AHA/ACC guidelines (ie, training and competing in places where an AED is available) are not always feasible in the real world [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a single-center retrospective cohort study of nearly 500 patients with LQTS who were managed with a return-to-play protocol and shared decision-making, the rates of breakthrough cardiac events (ie, seizures, syncope, cardiac arrest) among patients who returned to competitive sport were low [
         <a href="#rid16">
          16
         </a>
         ]. In 494 self-identified athletes who returned to play (mean age 14.8 ± 10.8 years), during follow-up for 4.2 ± 4.8 years, there were no sports-related deaths; 29 patients (5.9 percent) had nonlethal LQTS-associated breakthrough cardiac events, only three (0.6 percent) of which occurred during exercise.
        </p>
        <p class="headingAnchor" id="H1804037838">
         <span class="h3">
          Gene-specific management
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is an association between genotype and triggers of arrhythmia  (
         <a class="graphic graphic_figure graphicRef64239" href="/z/d/graphic/64239.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid17">
          17-20
         </a>
         ]. In particular:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with LQT1 primarily have exercise-related arrhythmic events; in a review that included 371 patients with LQT1, exercise was the trigger in 62 percent of arrhythmic events [
         <a href="#rid17">
          17
         </a>
         ]. In addition, events related to swimming (occurring either immediately after diving into water or during recreational or competitive swimming activities) may be specific for LQT1 [
         <a href="#rid19">
          19,21,22
         </a>
         ]. The sensitivity of patients with LQT1 to exercise may be related to exaggerated prolongation of the QT interval during exercise [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Events triggered by auditory stimuli, such as an alarm clock or telephone ringing, are most typically seen in LQT2 [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute arousal events (such as exercise, emotion, or noise) are much more likely triggers in LQT1 and LQT2 than LQT3 (85 and 67 versus 33 percent in one report) [
         <a href="#rid17">
          17,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with LQT3 are at highest risk of events when at rest or asleep, while the risk is low during sleep in LQT1, accounting for only 3 percent of events [
         <a href="#rid17">
          17
         </a>
         ]. Patients with LQT3 may have fewer events with exercise or stress because they significantly shorten their QTc with tachycardia [
         <a href="#rid24">
          24
         </a>
         ] and therefore become less susceptible to catecholamine-induced arrhythmias. (See
         <a class="local">
          'Beta blockers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3863152420">
         <span class="h2">
          Initial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with congenital LQTS and a history of syncope, seizures, or resuscitated SCA, we recommend treatment with a beta blocker [
         <a href="#rid8">
          8
         </a>
         ]. In general, we suggest
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         , given their superior efficacy in this patient population. The use of
         <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">
          atenolol
         </a>
         and
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         has been associated with an increased rate of recurrences [
         <a href="#rid25">
          25
         </a>
         ]. In addition, if the symptom was resuscitated SCA, then an ICD as secondary prevention is indicated as well in most circumstances. (See
         <a class="local">
          'Implantable cardioverter-defibrillator'
         </a>
         below.)
        </p>
        <p>
         Beta blockers are a mainstay of therapy in both asymptomatic and symptomatic patients with congenital LQTS since they reduce both syncope and SCD [
         <a href="#rid8">
          8
         </a>
         ]. Because of extensive observational data and expert consensus on the efficacy of beta blockers in this population, it is widely felt to be unethical to randomize patients to placebo, such that a randomized controlled trial in this population is unlikely. The overall benefit of beta-blocker therapy in congenital LQTS has been demonstrated in a number of observational studies, with many of the patients recruited from the International LQTS Registry [
         <a href="#rid17">
          17,26-30
         </a>
         ]. In a series of 869 registry patients treated with a beta blocker, in whom clinical event rates for the five-year periods before and after beta-blocker therapy were compared, treatment with beta blockers reduced the rate of cardiac events (eg, syncope, aborted cardiac arrest, or SCD) in probands (0.31 events per patient per year on therapy versus 0.97 events per patient per year off therapy) and in affected family members [
         <a href="#rid27">
          27
         </a>
         ]. Despite this benefit, 32 percent of patients with syncope or aborted SCA before beta-blocker therapy had another cardiac event during the five-year period while on a beta blocker (hazard ratio 5.8 compared with asymptomatic patients before therapy, 95% CI 3.7-9.1). Nearly one-half of these events occurred within the first six months of therapy  (
         <a class="graphic graphic_figure graphicRef78184" href="/z/d/graphic/78184.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
         The importance of compliance with beta-blocker therapy in LQT1 was highlighted in a retrospective study of 216 genotyped patients followed for a median time of 10 years [
         <a href="#rid31">
          31
         </a>
         ]. Among the 12 patients who suffered SCA or SCD after beta blockers were prescribed, 11 were either noncompliant with beta-blocker therapy and/or on a potentially contraindicated QT-prolonging drug. The only death in a beta-blocker-compliant patient not on a QT-prolonging drug occurred in a patient with Jervell and Lange-Nielsen syndrome, which is a more malignant form of LQT1. (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Congenital sensorineural deafness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4155705003">
         <span class="h4">
          Differences among various beta blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          Propranolol
         </a>
         (either given three times per day or extended-release formulations for improved compliance) and/or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         are the preferred beta blockers for therapy of LQTS, particularly for patients with LQT1 or LQT2.
        </p>
        <p>
         Because various beta blockers differ in their pharmacologic properties (eg, beta-1 selectivity, lipophilicity, half-life, etc), there appear to be differences in the efficacy of beta blockers on QT shortening and clinical outcomes. In a retrospective cohort study of 382 patients (56 percent female, median age 14 years) with LQT1 or LQT2 who were treated with
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         (134 patients),
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         (147 patients), or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         (101 patients) and followed for up to eight years, the following findings were noted [
         <a href="#rid25">
          25
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         had more significant QTc shortening (27 versus 14 versus 12 milliseconds with
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         and
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         , respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         had significantly more breakthrough clinical events (eg, syncope, aborted cardiac arrest, ICD shock, or SCD) compared with those receiving
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         (29 versus 8 versus 7 percent, respectively; odds ratio 3.9, 95% CI 1.2-13.1 for metoprolol versus any other beta blocker).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h4">
          Effect of genotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with LQT1 derive the greatest benefit, but beta-blocker therapy is also very effective for both LQT2 and LQT3 patients [
         <a href="#rid32">
          32
         </a>
         ]. The three genotypes (LQT1, LQT2, and LQT3) account for over 90 percent of known mutations in congenital LQTS [
         <a href="#rid33">
          33
         </a>
         ]. The clinical efficacy of beta blockers in relation to these genotype has been examined in several observational studies. [
         <a href="#rid17">
          17,27,28
         </a>
         ]
         <br/>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQT1
         </strong>
         – Beta blockers have relatively increased efficacy in LQT1 versus LQT3. This is probably related to the sympathetic sensitivity in this disorder. Most humans with LQT1 show paradoxical prolongation of the QT interval after an infusion of catecholamine, such as
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         . The epinephrine QT stress test was used in the past to unmask patients with concealed LQT1 [
         <a href="#rid34">
          34,35
         </a>
         ]. However, the test is subject to a large amount of interpretation error. Thus, genetic testing for LQTS has largely replaced the epinephrine QT stress test.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQT3
         </strong>
         – There is reduced efficacy of beta blockers in LQT3 compared with LQT1. Unlike patients with LQT1, patients with LQT3 shorten their QT interval with tachycardia [
         <a href="#rid24">
          24
         </a>
         ], making them less susceptible to catecholamine-induced arrhythmias. This could explain the comparatively reduced efficacy of beta blockers in LQT3 versus LQT1 and the lower rate of events triggered by exercise or stress in patients with the LQT3 subtype  (
         <a class="graphic graphic_figure graphicRef64239" href="/z/d/graphic/64239.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid17">
          17,27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1009.html" rel="external">
          "Congenital long QT syndrome: Pathophysiology and genetics", section on 'Type 1 LQTS (LQT1)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is some evidence that females with LQT3 may have greater benefit from beta blockers compared with men, although current data are insufficient to draw definite conclusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multicenter registry study, 391 LQT3 patients (aged 1 to 41 years) were followed for development of a first cardiac events or CE (syncope, aborted cardiac arrest, or long-QT-syndrome-related sudden death). Of these, 118 (77 females) patients experienced at least 1 CE, and 24 patients had LQT3-related aborted cardiac arrest/sudden death.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Time-dependent beta-blocker therapy was associated with an 83 percent reduction in CEs in females but not in males (who had many fewer events). Efficacy in males could not be determined conclusively because of the low number of events.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2510934825">
         <span class="h4">
          Oral contraceptive pills in females
         </span>
         <span class="headingEndMark">
          —
         </span>
         One observational study of 1600 females suggested that use of progestin-only oral contraceptive pills (OCPs) was associated with increased cardiac events in women not taking beta-blockers [
         <a href="#rid36">
          36
         </a>
         ]. Use of progestin-only OCPs was associated with the highest burden of cardiac events per 100 patient-years: 14.1 for progestin only, 6.2 in estrogen-only, 7.5 for combined, and 7 events in the no-OCP group. In contrast, in women who were treated with beta blockers, progestin-only OCP use was associated with fewer cardiac events (4.5 events per 100 patient years). Possible misclassification of OCP type and non-randomized design limit our ability to draw firm conclusions from this analysis.
        </p>
        <p class="headingAnchor" id="H1959912274">
         <span class="h2">
          Subsequent therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with recurrent arrhythmic events in spite of maximally tolerated doses of a beta blocker or in the setting of unacceptable beta-blocker-associated side effects, treatment intensification is pursued with either concomitant drug therapy, LCSD, and/or an ICD depending on the nature of the arrhythmic event, the genotype, and the patient's degree of QT prolongation at rest (ie, their resting QTc). Treatment intensification for patients with recurrent arrhythmic events should ideally take place in a center with expertise in the management of congenital LQTS, or for patients without access to an expert center, in consultation with a specialist with expertise in congenital LQTS.
        </p>
        <p class="headingAnchor" id="H2805876716">
         <span class="h3">
          Other pharmacologic therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a role for select other pharmacologic therapies targeted to specific subsets of congenital LQTS patients.
        </p>
        <p class="headingAnchor" id="H2134436323">
         <span class="h4">
          Potassium and/or spironolactone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine potassium supplementation/replacement and/or use of potassium-retaining medications like
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         is not generally indicated. However, for patients with malignant LQTS who continue to receive appropriate ICD shocks or who have a high-risk phenotype but prefer to avoid an ICD, potassium retention strategies are implemented, regardless of the underlying LQTS genotype.
        </p>
        <p class="headingAnchor" id="H405119259">
         <span class="h4">
          Mexiletine
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with LQT3,
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         pharmacotherapy is not only QT-attenuating but also confers a significant protective effect. Increasingly, combination therapy with
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         and mexiletine is utilized in patients with LQT3. Targeted dosing for mexiletine is generally 4 to 6 mg/kg/dose administered approximately every eight hours. Mexiletine trough levels can be obtained. Both mexiletine and propranolol are metabolized via cytochrome P4502D6 (CYP2D6) and approximately 10 percent of the White populations are either poor metabolizers of 2D6 substrates like mexiletine or are ultra-rapid metabolizers. CYP2D6 genotype status can be obtained to help guide dosing strategy.
        </p>
        <p>
         Although blocking the LQT3-associated accentuation of the late sodium current with
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         makes sense, in our authors’ experience, a significant QTc attenuation effect has also been seen in patients with other LQTS genotypes, particularly LQT2. As such, for patients with higher-risk LQT2, combination drug therapy with a beta blocker and mexiletine can be considered as well [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Left cardiac sympathetic denervation
         </span>
         <span class="headingEndMark">
          —
         </span>
         LCSD is an effective therapy in patients with congenital LQTS and persistent arrhythmias on beta blockers as well as in those who cannot tolerate beta blockers [
         <a href="#rid8">
          8,38-41
         </a>
         ]. While LCSD produces significant reductions in the number of subsequent cardiac events per patient overall, postdenervation recurrences can occur especially when the predenervation expressivity was malignant and extreme [
         <a href="#rid42">
          42
         </a>
         ]. However, in most patients, LCSD offers an additional risk reduction prior to considering an ICD, although it does not preclude ICD placement in appropriate high-risk patients.
        </p>
        <p>
         LCSD interrupts the major source of norepinephrine released in the heart via preganglionic denervation [
         <a href="#rid43">
          43
         </a>
         ]. Since denervation is preganglionic, there is no reinnervation. The procedure does not completely eliminate catecholamines in the ventricles, and it does not lead to post-denervation supersensitivity to catecholamines [
         <a href="#rid44">
          44
         </a>
         ]. LCSD is similarly effective across genotypes, when infants with events in the first year of life are not considered [
         <a href="#rid45">
          45-47
         </a>
         ]. LCSD is similarly effective in LQT1 and LQT2 patients [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Implantable cardioverter-defibrillator
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICDs are an important component of therapy for patients with congenital LQTS, particularly among patients who present with resuscitated SCA or those who have recurrent major events [
         <a href="#rid48">
          48-51
         </a>
         ]. However, complications, including infection, lead fracture and dislodgement, inappropriate discharges, and psychiatric sequelae, are not uncommon with ICDs (25 percent within five years) [
         <a href="#rid52">
          52
         </a>
         ]. For these reasons, it is not appropriate to consider ICDs in all patients with congenital LQTS. In fact, most patients with LQTS (90 percent or more in LQTS expert centers) do not need and should not receive an ICD just because they have been diagnosed with LQTS in general or even LQT3 in particular (where highest ICD implant rates have been noted). Instead, our approach to the utilization of ICDs in this population is as follows [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend an ICD in most patients whose initial presentation was SCA and in whom a reversible cause is not identified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We recommend an ICD in patients with LQTS-associated SCA while compliant with beta-blocker therapy. If an ICD was chosen instead of additional medications or LCSD following this on-therapy SCA, then LCSD therapy is often kept as a subsequent treatment option if an appropriate ICD shock occurs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although we generally recommend an ICD for patients with resuscitated SCA occurring prior to diagnosis of and treatment for their LQTS, it may be possible to assemble a non-ICD treatment program for some of these patients. However, this should be considered only in LQTS specialty centers because guidelines essentially recommend an ICD for any LQTS patient (diagnosed or previously undiagnosed) who experiences SCA [
         <a href="#rid8">
          8,12,13
         </a>
         ]. For example, one potential exception to this in our practices are patients with a sentinel event of SCA with previously undiagnosed and therefore untreated LQT1 substrate. For such LQT1 patients who are trying to avoid an ICD if at all possible, we have configured beta-blocker therapy plus LCSD as part of their initial treatment program.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest an ICD for patients with recurrent cardiac syncope in spite of beta blockers
         <strong>
          and
         </strong>
         LCSD, or for patients with recurrent cardiac syncope while taking beta blockers in whom LCSD is not an option.
        </p>
        <p>
        </p>
        <p>
         Importantly, an ICD is
         <strong>
          never
         </strong>
         indicated based solely on the family history. A family history of LQTS-associated SCD is not a personal risk factor for the patient with LQTS. Overall, most patients with LQTS do
         <strong>
          not
         </strong>
         need and should
         <strong>
          not
         </strong>
         receive an ICD. The vast majority of LQTS patients can be treated effectively without an ICD. Combined, among all of the patients with LQTS that are evaluated, risk stratified, and treated at expert LQTS centers, approximately 3 to 10 percent of them have an ICD [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4000903200">
         <span class="h3">
          Cardiac pacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac pacing is seldom utilized in isolation when treating patients with LQTS. For the patient with an indication for an ICD, a single-lead system is generally advised. If the patient then goes on to experience an appropriate ventricular fibrillation (VF)-terminating ICD shock where a bradycardia or long-short-long pause mechanism is documented, an upgrade to the device to include atrial pacing is sometimes performed. In our experience, the therapeutic role of atrial pacing, with an intentional lower rate limit of 80 beats per minute, may be best realized in women with LQT2 [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2900774606">
         <span class="h2">
          Our approach to asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic patients with congenital LQTS have different levels of risk for experiencing an LQTS-associated sentinel event, and it can be difficult to identify patients who will become symptomatic. Our general approach to asymptomatic patients with congenital LQTS is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As with symptomatic patients, asymptomatic patients with congenital LQTS should adhere to standard general preventive measures, such as the avoidance of medications known to prolong the QT interval and the aggressive treatment of electrolyte imbalances (eg, hypokalemia in the setting of vomiting, diarrhea, or diuretic use).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As with symptomatic patients, the 2015 AHA/ACC Scientific Statement supports continuation of competitive sports in asymptomatic patients with LQTS with appropriate cautionary measures, including an AED safety plan, while the European guidelines remain more restrictive. Some disagreement among experts persists, however. (See
         <a class="local">
          'Physical activity and LQTS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most asymptomatic patients with congenital LQTS, we suggest treatment with a beta blocker [
         <a href="#rid1">
          1
         </a>
         ]. In general, we prefer
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         . However, for asymptomatic patients with a QTc &lt;470 milliseconds, beta-blocker therapy may not always be required. Accordingly, there may be times when the risk-benefit calculus clearly favors intentional non-therapy with implementation of only the aforementioned preventative measures. As one example, beta-blocker therapy may not be necessary in the asymptomatic 55-year-old male with LQT1 and a resting QTc &lt;440 milliseconds. For asymptomatic patients who wish to follow preventative measures only and intentionally forego beta-blocker therapy, an evaluation with an LQTS specialist may be beneficial to best assess the potential for a sentinel event and the comfort/confidence with intentional non-therapy [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="local">
          'Beta blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In asymptomatic patients with either LQT2 or LQT3 whose resting QTc is &gt;550 milliseconds or postpubertal women with LQT2, a prophylactic LCSD at a lower QTc threshold (QTc &gt;500 milliseconds) is reasonable. These profiles in asymptomatic patients may warrant more aggressive surgical or device-related interventions.
         <br/>
         <br/>
         However, if the addition of QT-shortening therapies like
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         <strong>
         </strong>
         produced a now-on-therapy baseline QTc &lt;500 ms, we continue with pharmacotherapy alone, or add additional anti-fibrillatory protection with LCSD (rather than adding a prophylactic ICD) [
         <a href="#rid37">
          37,45,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with high-risk genetic mutations such as those in the KCNQ1 S6 region require closer and more aggressive therapy to prevent SCA/SCD [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3287378670">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116416.html" rel="external">
          "Society guideline links: Inherited arrhythmia syndromes"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">
          "Society guideline links: Ventricular arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H529791916">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86973.html" rel="external">
          "Patient education: Long QT syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Long QT syndrome (LQTS) is a disorder of ventricular myocardial repolarization characterized by a prolonged QT interval on the ECG  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ). LQTS can lead to symptomatic ventricular arrhythmias and an increased risk of sudden cardiac death (SCD). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients
         </strong>
         – Our general approach to treatment of symptomatic (or previously symptomatic) patients with congenital LQTS is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General measures
         </strong>
         – All patients with congenital LQTS should adhere to standard general preventive measures, such as the avoidance of medications known to prolong the QT interval (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=988" target="_blank">
          www.crediblemeds.org
         </a>
         ) and the aggressive treatment of electrolyte imbalances (eg, hypokalemia in the setting of vomiting, diarrhea, or diuretic use). (See
         <a class="local">
          'Our approach to symptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Activity
         </strong>
         – After establishing the correct diagnosis of LQTS and implementing the initial treatment program, patients with LQTS can continue to be recreationally active, especially those with LQT2 and LQT3. Athletes with LQTS who desire to remain athletes should be evaluated by an LQTS specialist to enable shared decision making to occur successfully. Importantly, there are laws in some countries that supersede professional society guidelines regarding return-to-play issues. (See
         <a class="local">
          'Physical activity and LQTS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Asymptomatic persons who are genotype positive/phenotype negative (ie, with normal QTc at rest) can reasonably participate in all competitive sports with appropriate safety precautions.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Symptomatic (or previously symptomatic) patients, or patients with LQTS (QTc &gt;470 milliseconds in males or &gt;480 milliseconds in females) may consider participation in competitive athletics (with the possible exception of swimming in patients with LQT1 genotype) if they remain asymptomatic after three months of treatment and with appropriate cautionary measures, including an emergency action plan with an automated external defibrillator immediately available. Local laws and regulations may apply.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Experts disagree on participation in higher levels of sport for patients with an implantable cardioverter-defibrillator (ICD) in place, with some experts allowing participation following counselling of the patient of potential risks and appropriate cautionary measures, while other experts feel it is unwise to expose patients to the risk of ventricular arrhythmias and multiple shocks just to perform a competitive sport.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Beta blockers
         </strong>
         – For all patients with congenital LQTS and a history of syncope or seizures, we recommend treatment with a beta blocker (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         , given their superior efficacy in this patient population (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Beta blockers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Implantable cardiac defibrillator
         </strong>
         – Patients with LQTS-associated sudden cardiac arrest (SCA), while compliant with beta-blocker therapy, should generally receive an ICD. Importantly, self-limiting syncope/seizures, even if assessed to be LQTS-triggered (ie, secondary to TdP) are
         <strong>
          not
         </strong>
         equivalent to SCA. (See
         <a class="local">
          'Implantable cardioverter-defibrillator'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment intensification
         </strong>
         – For patients with recurrent, LQTS-triggered arrhythmic events in spite of maximally tolerated doses of a beta blocker, or for patients who discontinue beta blockers due to intolerable side effects, treatment intensification is pursued with either concomitant drug therapy, left cardiac sympathetic denervation, and/or an ICD depending on the nature of the arrhythmic event, the genotype, and the patient's degree of QT prolongation at rest (ie, their resting QTc). Treatment intensification for patients with recurrent arrhythmic events should ideally take place in a center with expertise in the management of congenital LQTS, or for patients without access to an expert center, in consultation with a specialist with expertise in congenital LQTS. (See
         <a class="local">
          'Subsequent therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic patients
         </strong>
         – Our general approach to treatment of
         <strong>
          asymptomatic
         </strong>
         patients with congenital LQTS is as follows (see
         <a class="local">
          'Our approach to asymptomatic patients'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most asymptomatic patients with congenital LQTS, we suggest a beta blocker (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In general, the choice of a beta blocker is the same as in symptomatic patients (ie,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">
          nadolol
         </a>
         ). However, for asymptomatic patients with a QTc &lt;470 milliseconds, beta-blocker therapy may not be required.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If an asymptomatic patient with either LQT2 or LQT3 maintains a QTc &gt;550 ms while on pharmacotherapy, we suggest either a prophylactic left cardiac sympathetic denervation (LCSD) or a prophylactic ICD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For postpubertal women with LQT2, either prophylactic LCSD or a prophylactic ICD at a lower QTc threshold (QTc &gt;500 milliseconds) is reasonable again if pharmacotherapy (namely
         <a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">
          mexiletine
         </a>
         ) has not attenuated the QTc to &lt;500 ms. Importantly, an ICD is
         <strong>
          never
         </strong>
         indicated based solely on a family history of LQTS-associated SCD, as family history is not a personal risk factor for the patient.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 2013; 34:3109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002; 112:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wehrens XH, Vos MA, Doevendans PA, Wellens HJ. Novel insights in the congenital long QT syndrome. Ann Intern Med 2002; 137:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camm AJ, Janse MJ, Roden DM, et al. Congenital and acquired long QT syndrome. Eur Heart J 2000; 21:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000; 36:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AAM. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013; 62:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97:2237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zareba W, Moss AJ, Schwartz PJ, et al. Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998; 339:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagradi F, Spazzolini C, Castelletti S, et al. Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. Circulation 2020; 142:2405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turkowski KL, Bos JM, Ackerman NC, et al. Return-to-Play for Athletes With Genetic Heart Diseases. Circulation 2018; 137:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobert KE, Bos JM, Garmany R, Ackerman MJ. Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death. J Am Coll Cardiol 2021; 78:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999; 33:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali RH, Zareba W, Moss AJ, et al. Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000; 85:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999; 74:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batra AS, Silka MJ. Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome. J Pediatr 2002; 141:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takenaka K, Ai T, Shimizu W, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92:3381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012; 60:2092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007; 49:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006; 296:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008; 117:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation 2009; 119:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilde AA, Moss AJ, Kaufman ES, et al. Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. Circulation 2016; 134:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Khositseth A, Tester DJ, et al. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003; 41:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg I, Younis A, Huang DT, et al. Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm 2022; 19:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bos JM, Crotti L, Rohatgi RK, et al. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. Circ Arrhythm Electrophysiol 2019; 12:e007280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collura CA, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009; 6:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ. 1970-2020: 50 years of research on the long QT syndrome-from almost zero knowledge to precision medicine. Eur Heart J 2021; 42:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusi V, Pugliese L, De Ferrari GM, et al. Left Cardiac Sympathetic Denervation for the Long QT Syndrome. 50 Years’ experience provides guidance for management. JACC Clin Electrophysiol 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders. Circ Arrhythm Electrophysiol 2013; 6:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ. The rationale and the role of left stellectomy for the prevention of malignant arrhythmias. Ann N Y Acad Sci 1984; 427:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Stone HL. Left stellectomy and denervation supersensitivity in conscious dogs. Am J Cardiol 1982; 49:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusi V, Pugliese L, De Ferrari GM, et al. Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management. JACC Clin Electrophysiol 2022; 8:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Snebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol 1976; 37:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J 2022; 43:2096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr 2009; 168:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 2007; 50:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proclemer A, Ghidina M, Facchin D, et al. Use of implantable cardioverter-defibrillator in inherited arrhythmogenic diseases: data from Italian ICD Registry for the years 2001-6. Pacing Clin Electrophysiol 2009; 32:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010; 122:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowlgi GN, Giudicessi JR, Barake W, et al. Efficacy of intentional permanent atrial pacing in the long-term management of congenital long QT syndrome. J Cardiovasc Electrophysiol 2021; 32:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIntyre CJ, Rohatgi RK, Sugrue AM, et al. Intentional nontherapy in long QT syndrome. Heart Rhythm 2020; 17:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzanti A, Maragna R, Faragli A, et al. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. J Am Coll Cardiol 2016; 67:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Moreno C, Kotta MC, et al. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. Eur Heart J 2021; 42:4743.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 988 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23509228" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14999113" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Drug-induced prolongation of the QT interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11812408" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical and therapeutic aspects of congenital and acquired long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12484714" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Novel insights in the congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924312" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Congenital and acquired long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10898405" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The long QT syndromes: genetic basis and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684683" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of genetics on the clinical management of channelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9631873" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753711" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33073610" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26542662" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26542670" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15923204" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29507000" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Return-to-Play for Athletes With Genetic Heart Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34330632" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136691" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9973011" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10532503" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10728950" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10560595" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12183730" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12591753" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8521555" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23083782" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239714" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long QT syndrome in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10673253" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367556" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16968849" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18427136" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118258" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27566755" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10973849" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12004990" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12598076" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34339849" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Use of oral contraceptives in women with congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31006312" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051644" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467503" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33057695" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : 1970-2020: 50 years of research on the long QT syndrome-from almost zero knowledge to precision medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Left Cardiac Sympathetic Denervation for the Long QT Syndrome. 50 Years’experience provides guidance for management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23728945" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6331251" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The rationale and the role of left stellectomy for the prevention of malignant arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6175200" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Left stellectomy and denervation supersensitivity in conscious dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35331422" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1274864" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35301528" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19101729" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : QT interval prolongation and risk for cardiac events in genotyped LQTS-index children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12741701" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Implantable cardioverter defibrillator in high-risk long QT syndrome patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17903632" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long QT syndrome in children in the era of implantable defibrillators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19335851" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of implantable cardioverter-defibrillator in inherited arrhythmogenic diseases: data from Italian ICD Registry for the years 2001-6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20837891" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33512040" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of intentional permanent atrial pacing in the long-term management of congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32105774" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Intentional nontherapy in long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26940925" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34505893" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
